The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Compare top high-yield ETFs by income potential and durability to select funds that optimize retirement cash flow and resilience.
27,330 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Microsoft stock moved higher in a day of broad market gains. This article breaks down the top drivers behind the surg...
A new line of thinking from Google DeepMind suggests AI consciousness debates may spill into policy and crypto govern...
March brought a mix of regulatory headlines and upbeat AI-related gains. This article breaks down what happened in th...
Six upcoming real estate events conferences for 2026 offer networking, market intelligence, and practical strategies ...
A biotech growth stock has surged 70% this year as it heads into pivotal phase 3 data and regulatory steps. Here’s wh...
A major fund recently disclosed a large move in Globalstar as the stock surged. This article explains what happened, ...
A new class of job-search firms charges up front fees to run an entire hunt for candidates. The market that reverse r...
Regulators in the UK are turning up the heat on crypto perpetual contracts. The latest wave centers on Hyperliquid an...
OpenAI reportedly considers delaying its IPO, placing AI stocks in the spotlight. This guide breaks down the potentia...
Palantir has surprised and divided investors with big moves and bold AI promises. This guide explains what to watch, ...
BlackRock's Larry Fink presents two stark paths for oil and markets tied to the Iran conflict, challenging households...